Update on the pharmacological treatment of resistant depression

Resistance to major depressive disorder treatment causes distress to patients and their relatives, increases the number of hospital admissions, outpatient consultations, use of psychoactive drugs, and treatment costs. We review the concept and definition of treatment-resistant depression (TRD), different treatment methods, and comparative studies on treatment strategies. Despite its serious medical and psychosocial implications, the pharmacological treatment of TRD continues to be non-standardized and controversial. More research and comparative controlled studies on different treatments for resistant depression, which include neurobiological evaluations, need to be done.

• Publication year

  2019

• Venue

  Revista Medicina Universitaria

• Publication date

  2019-08-09

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.24875/RMU.19000059
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Response to serotonergic and noradrenergic antidepressants: a crossover study of fluoxetine and desipramine in patients with first major depression episode

  2019cited by this paper
• Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials

  2018cited by this paper
• Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial

  2017cited by this paper
• Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial

  2017cited by this paper
• Combining Antidepressants in Acute Treatment of Depression: A Meta-Analysis of 38 Studies Including 4511 Patients

  2016cited by this paper
• Switching the Antidepressant After Nonresponse in Adults With Major Depression: A Systematic Literature Search and Meta-Analysis.

  2016cited by this paper
• Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials

  2015cited by this paper
• Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.

  2015cited by this paper
• Pharmacological approaches to the challenge of treatment-resistant depression

  2015cited by this paper
• The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review

  2014cited by this paper
• Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.

  2013cited by this paper
• Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

  2013cited by this paper
• European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings.

  2012cited by this paper
• The hidden third: improving outcome in treatment-resistant depression

  2012cited by this paper
• L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.

  2012cited by this paper
• Staging methods for treatment resistant depression. A systematic review.

  2012cited by this paper
• Treating Depression After Initial Treatment Failure: Directly Comparing Switch and Augmenting Strategies in STAR*D

  2012cited by this paper
• A Pilot Study of the Efficacy and Safety of Paroxetine Augmented With Risperidone, Valproate, Buspirone, Trazodone, or Thyroid Hormone in Adult Chinese Patients With Treatment-Resistant Major Depression

  2011cited by this paper
• Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD)

  2010cited by this paper
• An algorithm for the pharmacological treatment of depression

  2010cited by this paper
• S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.

  2010cited by this paper
• Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.

  2010cited by this paper
• Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.

  2009cited by this paper
• Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines

  2008cited by this paper
• Nicotinic Antagonist Augmentation of Selective Serotonin Reuptake Inhibitor-Refractory Major Depressive Disorder: A Preliminary Study

  2008cited by this paper
• Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches.

  2008cited by this paper
• Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.

  2008cited by this paper
• Prevalence and management of treatment-resistant depression.

  2007cited by this paper
• Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials.

  2007cited by this paper
• What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials.

  2007cited by this paper
• Coadministration of Modafinil and a Selective Serotonin Reuptake Inhibitor From the Initiation of Treatment of Major Depressive Disorder With Fatigue and Sleepiness: A Double-Blind, Placebo-Controlled Study

  2007cited by this paper
• Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

  2006cited by this paper
• Medication augmentation after the failure of SSRIs for depression.

  2006cited by this paper
• Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.

  2006cited by this paper
• Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.

  2006cited by this paper
• Once-daily high-dose pindolol for SSRI-refractory depression.

  2004cited by this paper
• Diagnosis and definition of treatment-resistant depression.

  2003cited by this paper
• Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression.

  2002cited by this paper
• Using treatment algorithms for the effective management of treatment-resistant depression.

  2001cited by this paper
• Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies.

  2000cited by this paper
• Treatment resistant depression: methodological overview and operational criteria.

  1999cited by this paper
• SSRIs versus tricyclic antidepressants in depressed inpatients: A meta‐analysis of efficacy and tolerability

  1998cited by this paper
• A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.

  1998cited by this paper
• When at first you don't succeed: sequential strategies for antidepressant nonresponders.

  1997cited by this paper
• The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression.

  1997cited by this paper
• Treatment of refractory depression

  1997cited by this paper
• Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis.

  1996cited by this paper
• A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression.

  1993cited by this paper
• Common treatment problems in depression

  1985cited by this paper

• No citing papers are available for this paper.